Bladder cancer: An overview

CA: A Cancer Journal for Clinicians

Volumn 38, Issue 4, 1988, Pages 213-223

  Whitmore, Willet F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; HUMAN; PRIORITY JOURNAL; REVIEW;

BLADDER NEOPLASMS; FEMALE; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING;

EID: 0023730025     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.38.4.213     Document Type: Article

References (63)

1. Cancer statistics, 1988
2. Blasingeschwulste bei Fuchsin Arbeitern
3. An epidemiological investigation of cancer of the bladder
4. Tobacco as a risk factor in bladder cancer
5. Bladder cancer and cigarette smoking in males: A case‐control study
6. An international study of smoking and bladder cancer
7. Artificial sweeteners and bladder cancer in Manchester, UK and Nagoya, Japan
8. Artificial sweeteners and absence of bladder cancer risk in Copenhagen
9. Artificial sweeteners and cancer of the lower urinary tract
10. Malignancies of the urinary tract and their relation to analgesic abuse
11. Analgesic‐associated nephropathy and transitional cell carcinoma of the urinary tract
12. Does cyclophosphamide induce bladder cancer?
13. Simultaneous occurrence of transitional, squamous and adenocarcinoma of the bladder after 15 years of cyclophosphamide ingestion
14. Uroepithelial carcinoma in association with cyclophosphamide ingestion
15. Cancer of the bladder and infestation with Schistosoma hematobium
16. Guest editorial: Schistosomiasis and neoplasia
17. Malignant vesical tumors following spinal cord injury
18. Coffee drinking and cancer of the lower urinary tract
19. Coffee drinking and risk of bladder cancer
20. Second cancers following radiation treatment for cervical cancer: An international collaboration among cancer registries
21. Multistage carcinogenesis in the urinary bladder
22. Asymptomatic microscopic hematuria
23. The significance of asymptomatic microhematuria in men 50 or more years old: Findings of a home screening study using urinary dipsticks
24. The evaluation of microscopic hematuria: A population‐based study
25. Urinary cytology and bladder cancer: The cellular features of transitional cell neoplasms
26. Diagnostic value of cytology of voided urine
27. Reliability of urinary cytodiagnosis in urothelial neoplasms
28. Flow cytometry in bladder cancer detection and evaluation using acridine orange metachromatic nucleic acid staining of irrigation cytology specimens
29. Flow cytometry based on heterogeneity index score compared with urine cytology to evaluate their diagnostic efficacy in bladder tumor
30. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma
31. The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma
32. Current state of classification and staging of bladder cancer
33. Introduction: Assessment and management of deeply invasive and metastatic lesions
34. Infiltrating carcinoma of the bladder: Relation of depth of penetration of the bladder wall to incidence of local extension and metastases
35. The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms
36. The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
37. The value of excretory urography in staging bladder cancer
38. Surgical management of low stage bladder cancer
39. Conservative management of muscle‐infiltrating bladder cancer: Prospective experience
40. The biology and treatment of superficial bladder cancer
41. Experience with laser energy in urologic surgery
42. Laser photodynamic therapy for bladder cancer
43. O) treated either by radium implant or by transurethral resection only
44. Rationale for intensive intravesical chemotherapy for superficial bladder cancer
45. Surgery and intravesical chemotherapy in the management of superficial bladder cancer
46. Superficial carcinoma of the bladder: Natural history and the role of interferons
47. Superficial bladder cancer: The primacy of grade in the development of invasive disease
48. Review article: An overview of intravesical therapy for superficial bladder tumors
49. Status of integrated irradiation and cystectomy for bladder cancer
50. Papilloma of the urinary bladder
51. Transitional cell neoplasms of the urinary bladder: Can biologic potential be predicted from histologic grading?
52. Management of bladder cancer
53. T3 bladder cancer—the case for salvage cystectomy
54. Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy
55. The heterogeneity of invasive bladder carcinoma and different responses to treatment
56. Factors of prognostic and therapeutic significance in patients with bladder cancer
57. Chemotherapy for advanced urothelial cancer
58. Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study
59. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases
60. Preliminary results of M‐VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium